3 startups developing blood tests to help detect cancer earlier

Three startups with funding from major technologies companies are working to receive FDA approval on blood tests that screen for cancer, according to CNBC.

Freenome, a startup with backing from Alphabet's Verily, has developed a blood test that detects two major biomarkers in patients' blood in order to help identify early stage colorectal cancer. Additionally, the blood test is designed to find tiny fragments of DNA from a tumor in patients' bloodstream.

With support from Amazon, Grail is developing blood tests that can identify multiple types of cancers.

Similar to Grail, startup Thrive wants to commercialize a blood test developed by researchers at Baltimore-based Johns Hopkins that detects cancer. Thrive's blood test currently can identify pancreatic and ovarian cancers. The company recently secured financing from former Google Ventures chief Bill Maris.

To read more, click here.

More articles on health IT:
10 recent vendor contracts, go-lives
How Connecticut is developing a multimillion-dollar statewide HIE
CHIME, HIMSS name Marc Probst 'CIO of the Year'

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months